Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > “Second mouse gets the cheese “

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 11, 2024 11:46am

60 Views

Post# 36306672

RE:RE:RE:RE:“Second mouse gets the cheese “

A single late stage clinical study in non-invasive/muscle invasive bladder cancer using an intravesically administered OV in combination with an immune checkpoint inhibitor (nivolumab) has CG Oncology trading at US$40 p/s and a market cap of US$2.9 Billion

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant